Why it matters now
The global pandemic significantly accelerated the adoption of decentralized clinical trial (DCT) methodologies, proving their value in maintaining research continuity. As the immediate crisis subsides, the industry is evaluating the sustained utility and integration of these models. Companies must now determine the optimal balance between traditional and decentralized approaches, considering factors like patient engagement, data quality, and operational efficiency. Strategic decisions made now will shape future clinical development paradigms and competitive advantage.
Who is exposed
Pharmaceutical companies face impacts on trial costs, timelines, and patient recruitment, requiring adjustments to R&D budgets. Contract research organizations must evolve their service offerings and technology infrastructure to meet changing client demands. Technology providers in the DCT space are exposed to shifts in demand for their platforms and services, influencing their product development and market positioning.
Most relevant for: Head of Clinical Operations, R&D Director, Chief Digital Officer
What this Viewpoint covers
- What is the current prevalence of DCT components in new clinical trials?
- How have regulatory bodies adapted guidance for DCTs post-pandemic?
- Which therapeutic areas are showing sustained or increased DCT adoption?
- What are the key drivers and barriers to broader DCT implementation?
- How are technology solutions evolving to support hybrid and fully decentralized models?
Signals to watch
- New guidance or recommendations from regulatory agencies on DCTs.
- Investment trends in DCT technology platforms and services.
- Publications or presentations on DCT best practices and outcomes.
- Partnerships between pharmaceutical companies and DCT solution providers.
Decisions it supports
- Optimizing clinical trial design to incorporate appropriate DCT elements.
- Investing in technology platforms to support decentralized research.
- Developing operational strategies for hybrid and fully decentralized trials.
How it is built
Prepared after your order from dated public sources - such as pharma & biotech filings and announcements, regulatory records, trials, patents and trade data, where relevant - and our market model. Reported facts are cited, estimates are labelled and our assessment is marked as such, following our research method. You receive our verdict, the evidence, who is exposed, the signals to watch and recommended actions, within 24 hours.
Questions
What are decentralized clinical trials (DCTs)?
Decentralized clinical trials (DCTs) incorporate elements that allow some or all trial activities to occur remotely, outside of traditional clinical sites. This can include remote monitoring, telemedicine visits, direct-to-patient drug delivery, and wearable devices, aiming to enhance patient convenience and access.
Why is understanding DCT adoption important now?
After a surge in DCT use during the pandemic, the industry is evaluating their long-term viability and optimal application. Understanding current adoption trends helps companies make informed decisions about integrating DCTs into their standard operating procedures and future development pipelines.
Does this Viewpoint predict future DCT market size?
This Viewpoint analyzes the drivers and barriers influencing the continued uptake of DCTs, providing insights into their sustained integration into clinical development. It focuses on the strategic implications of adoption trends rather than providing market size forecasts.